{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:56:42Z","timestamp":1793120202663,"version":"4.5.0"},"reference-count":12,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Methylphenidate can treat attention-deficit\/hyperactivity disorders, which are frequently comorbid with bipolar disorders (BDs). Viktorin and collaborators (2017) reported that prescribing methylphenidate alone in adults with BD is associated with higher risk of manic relapse, whereas prescribing it in combination with mood-stabilizing medications is associated with lower risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>We aimed to replicate these findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We identified adults with BD included in the French national healthcare claims database (SNDS) between 2008 and 2024. We compared the rate of manic relapse within 6\u2009months before and after a new methylphenidate dispensation using self-controlled survival analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results\/outcomes:<\/jats:title>\n                    <jats:p>Among 2745 patients not receiving mood-stabilizing treatment, the rate of inpatient mania diagnoses was significantly higher within 3\u2009months of methylphenidate dispensation compared to the pre-exposure period. This significance disappeared in self-controlled case-crossover analyses. Among 3526 patients receiving continuous mood-stabilizing treatment, there were no significant changes in the risk of an inpatient mania diagnosis after methylphenidate dispensation, except when administering &gt;30\u2009mg of methylphenidate. Treating the start of new antimanic therapy as an outcome event produced outlier results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions\/interpretation:<\/jats:title>\n                    <jats:p>In patients with treated BD, methylphenidate is only associated with manic relapse at high dose. The strong significant risk of manic relapse we observed in untreated BD may be explained by natural progression of mania. This study highlights intrinsic limitations associated with self-controlled survival analysis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811261443684","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T14:10:55Z","timestamp":1778767855000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Methylphenidate and manic relapse in bipolar disorders: A replication study in a nationwide claims database"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1396-470X","authenticated-orcid":false,"given":"Nathan","family":"Vidal","sequence":"first","affiliation":[{"name":"Centre Hospitalier de Versailles, Service Universitaire de Psychiatrie d\u2019Adultes et d\u2019Addictologie, Le Chesnay, France"},{"name":"Facult\u00e9 de M\u00e9decine Paris-Saclay, MOODS Team, INSERM UMR1018, CESP, Universit\u00e9 de Versailles Saint-Quentin-En-Yvelines, Universit\u00e9 Paris-Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sol\u00e8ne","family":"Frileux","sequence":"additional","affiliation":[{"name":"Centre Hospitalier de Versailles, Service Universitaire de Psychiatrie d\u2019Adultes et d\u2019Addictologie, Le Chesnay, France"},{"name":"Facult\u00e9 de M\u00e9decine Paris-Saclay, MOODS Team, INSERM UMR1018, CESP, Universit\u00e9 de Versailles Saint-Quentin-En-Yvelines, Universit\u00e9 Paris-Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Younes","sequence":"additional","affiliation":[{"name":"Centre Hospitalier de Versailles, Service Universitaire de Psychiatrie d\u2019Adultes et d\u2019Addictologie, Le Chesnay, France"},{"name":"Facult\u00e9 de M\u00e9decine Paris-Saclay, DevPsy-CESP, INSERM UMR1018, CESP, Universit\u00e9 de Versailles Saint-Quentin-En-Yvelines, Universit\u00e9 Paris-Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Corruble","sequence":"additional","affiliation":[{"name":"Facult\u00e9 de M\u00e9decine Paris-Saclay, MOODS Team, INSERM UMR1018, CESP, Universit\u00e9 de Versailles Saint-Quentin-En-Yvelines, Universit\u00e9 Paris-Saclay, Villejuif, France"},{"name":"Service Hospitalo-Universitaire de Psychiatrie de Bic\u00eatre. H\u00f4pital Bic\u00eatre, AP-HP, Le Kremlin-Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Brunet-Gouet","sequence":"additional","affiliation":[{"name":"Centre Hospitalier de Versailles, Service Universitaire de Psychiatrie d\u2019Adultes et d\u2019Addictologie, Le Chesnay, France"},{"name":"Facult\u00e9 de M\u00e9decine Paris-Saclay, MOODS Team, INSERM UMR1018, CESP, Universit\u00e9 de Versailles Saint-Quentin-En-Yvelines, Universit\u00e9 Paris-Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0321-4189","authenticated-orcid":false,"given":"Paul","family":"Roux","sequence":"additional","affiliation":[{"name":"Centre Hospitalier de Versailles, Service Universitaire de Psychiatrie d\u2019Adultes et d\u2019Addictologie, Le Chesnay, France"},{"name":"Facult\u00e9 de M\u00e9decine Paris-Saclay, MOODS Team, INSERM UMR1018, CESP, Universit\u00e9 de Versailles Saint-Quentin-En-Yvelines, Universit\u00e9 Paris-Saclay, Villejuif, France"},{"name":"Service de Psychiatrie du Secteur 78G18, Centre Hospitalier de Plaisir, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"e_1_3_3_2_1","unstructured":"Amerio A Aguglia A Odone A et al. (2020) Covid-19 pandemic impact on mental health of vulnerable populations. Acta Biomedica 91: 95\u201396. https:\/\/doi.org\/10.23750\/abm.v91i9-S.10112"},{"key":"e_1_3_3_3_1","doi-asserted-by":"crossref","unstructured":"Barbuti M Menculini G Verdolini N et al. (2023) A systematic review of manic\/hypomanic and depressive switches in patients with bipolar disorder in naturalistic settings: The role of antidepressant and antipsychotic drugs. European Neuropsychopharmacology 73: 1\u201315. https:\/\/doi.org\/10.1016\/j.euroneuro.2023.04.013","DOI":"10.1016\/j.euroneuro.2023.04.013"},{"key":"e_1_3_3_4_1","doi-asserted-by":"crossref","unstructured":"Bezin J Duong M Lassalle R et al. (2017) The national healthcare system claims databases in France SNIIRAM and EGB: Powerful tools for pharmacoepidemiology. Pharmacoepidemiology and Drug Safety 26: 954\u2013962. https:\/\/doi.org\/10.1002\/pds.4233","DOI":"10.1002\/pds.4233"},{"key":"e_1_3_3_5_1","doi-asserted-by":"crossref","unstructured":"Chang Y Hsieh M-H Ju P-C et al. (2025) Antidepressant initiation and the risk of treatment-emergent mania in children and adolescents with depression: A real-world cohort study. Journal of Psychopharmacology 39: 1378\u20131386. https:\/\/doi.org\/10.1177\/02698811251389541","DOI":"10.1177\/02698811251389541"},{"key":"e_1_3_3_6_1","doi-asserted-by":"crossref","unstructured":"Chiorean A Jones BDM Murong M et al. (2024) Prescribed psychostimulants and other pro-cognitive medications in bipolar disorder: A systematic review and meta-analysis of recurrence of manic symptoms. Bipolar Disorder 26: 418\u2013430. https:\/\/doi.org\/10.1111\/bdi.13440","DOI":"10.1111\/bdi.13440"},{"key":"e_1_3_3_7_1","doi-asserted-by":"crossref","unstructured":"Clark P Rosenberg P Oh ES et al. (2024) Methylphenidate for the treatment of post-COVID cognitive dysfunction (Brain Fog). Journal of Medical Cases 15: 195\u2013200. https:\/\/doi.org\/10.14740\/jmc4254","DOI":"10.14740\/jmc4254"},{"key":"e_1_3_3_8_1","doi-asserted-by":"crossref","unstructured":"Maldonado R (2013) Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate. Expert Opinion on Drug Metabolism & Toxicology 9: 1001\u20131014. https:\/\/doi.org\/10.1517\/17425255.2013.786041","DOI":"10.1517\/17425255.2013.786041"},{"key":"e_1_3_3_9_1","doi-asserted-by":"crossref","unstructured":"Perugi G Vannucchi G Bedani F et al. (2017) Use of stimulants in bipolar disorder. Current Psychiatry Reports 19: 7. https:\/\/doi.org\/10.1007\/s11920-017-0758-x","DOI":"10.1007\/s11920-017-0758-x"},{"key":"e_1_3_3_10_1","doi-asserted-by":"crossref","unstructured":"Pompili M Baldessarini R Forte A et al. (2016) Do atypical antipsychotics have antisuicidal effects? A hypothesis-generating overview. International Journal of Molecular Sciences 17: 1700. https:\/\/doi.org\/10.3390\/ijms17101700","DOI":"10.3390\/ijms17101700"},{"key":"e_1_3_3_11_1","unstructured":"Qiu W Chavarro J Lazarus R et al. (2025) powerSurvEpi: Power and Sample Size Calculation for Survival Analysis of Epidemiological Studies. R package version 0.1.5. https:\/\/CRAN.R-project.org\/package=powerSurvEpi"},{"key":"e_1_3_3_12_1","doi-asserted-by":"crossref","unstructured":"Viktorin A Ryd\u00e9n E Thase ME et al. (2017) The risk of treatment-emergent mania with methylphenidate in bipolar disorder. The American Journal of Psychiatry 174: 341\u2013348. https:\/\/doi.org\/10.1176\/appi.ajp.2016.16040467","DOI":"10.1176\/appi.ajp.2016.16040467"},{"key":"e_1_3_3_13_1","doi-asserted-by":"crossref","unstructured":"Yatham LN Kennedy SH Parikh SV et al. (2018) Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorder 20: 97\u2013170. https:\/\/doi.org\/10.1111\/bdi.12609","DOI":"10.1111\/bdi.12661"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261443684","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811261443684","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261443684","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T07:47:14Z","timestamp":1779176834000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811261443684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":12,"alternative-id":["10.1177\/02698811261443684"],"URL":"https:\/\/doi.org\/10.1177\/02698811261443684","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"article-number":"02698811261443684"}}